Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.37 |
| ▸ | PARG | Q86W56 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | GALR3 | O60755 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4715382 | 0.91 | FEN1 (0.47) | NOX4FEN1RXFP1DPP4ALDH1A1 | |
| SCHEMBL4789540 | 0.85 | MAPT (0.49) | NOX4FEN1RXFP1ALDH1A1NPSR1 | |
| SCHEMBL4714667 | 0.75 | PLA2G10 (0.47) | FEN1ALDH1A1THRB | |
| SCHEMBL4715213 | 0.75 | CCR2 (0.51) | ALDH1A1 | |
| SCHEMBL4715856 | 0.73 | CCR2 (0.40) | ALDH1A1 | |
| SCHEMBL4712363 | 0.73 | CCR2 (0.50) | — | |
| SCHEMBL8688625 | 0.68 | ALDH1A1 (0.60) | NOX4FEN1RXFP1DPP4ALDH1A1 | |
| SCHEMBL4715522 | 0.67 | RGS4 (0.48) | RXFP1 | |
| SCHEMBL4711636 | 0.66 | MEN1 (0.47) | FEN1ALDH1A1THRB | |
| SCHEMBL4716102 | 0.66 | MAPT (0.57) | ALDH1A1NPSR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456286-B2 | Bicyclic heteroaromatic compounds as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2008-11-25 | — | — | US | claimed |
| US-20060122212-A1 | Bicyclic heteroaromatic compounds as kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2006-06-08 | — | — | US | claimed |
| US-7456286-B2 | Bicyclic heteroaromatic compounds as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2008-11-25 | — | — | US | disclosed |
| EP-1549648-B1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2008-11-12 | — | — | EP | disclosed |
| US-20060122212-A1 | Bicyclic heteroaromatic compounds as kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2006-06-08 | — | — | US | disclosed |
| EP-1549648-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS | Celltech R & D Limited (GB) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004031188-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS | CELLTECH R & D LIMITED (GB) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122212-A1 | Bicyclic heteroaromatic compounds as kinase inhibitors | MAP2K2, MAP2K7, MAP2K3 | NOX4 865/4885FEN1 2339/4885RXFP1 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.